TARDBP and proteostasis deficiencies: The drug Riluzole, commonly used to treat ALS, has been discovered to have micromolar inhibitory activity towards protein kinase CK1δ, indicating a link between its action and the inhibition of CK1δ, which prevents TDP-43 hyperphosphorylation, and presenting new opportunities for the development of more potent treatments for ALS and other TDP-43 related proteinopathies [88].